Nasdaq · CIK 0001326190
ALT Altimmune, Inc.
Insider trading from SEC Form 4. Last filing 8 d ago. Close $2.61 on Oct 9, 2026, +1% from the 52-week low and -58% from the high.
Altimmune, Inc. (ALT) has 67 SEC Form 4 filings on file from 16 insiders, the latest filed on Oct 5, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
12 open-market trades have been scored at ALT. The newest: John Gill (director) bought $31k of stock on Apr 6, 2026, filed Apr 6, 2026, scored 53 (moderate). The largest of the 12 shown: Jerome Benedict Durso (President and CEO) bought $71k on Mar 6, 2026, scored 74 (notable). 3 insiders bought within 14 days of each other around Apr 6, 2026.
ALT closed at $2.61 on Oct 9, 2026, 1% above its 52-week low and 58% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Altimmune, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 53Moderate | John Gill director buy | $31k 9,200 shares | +74% | +16% from low-57% from high | |
| 71Notable | Gregory L Weaver Chief Financial Officer buy | $31k 10,000 shares | +36% | +8% from low-60% from high | |
| 75Notable | Jerome Benedict Durso President and CEO buy | $47k 15,000 shares | +46% | +8% from low-60% from high | |
| 54Moderate | Gregory L Weaver Chief Financial Officer buy | $18k 5,000 shares | +22% | +5% from low-54% from high | |
| 74Notable | Jerome Benedict Durso President and CEO buy | $71k 20,000 shares | +160% | +5% from low-54% from high | |
| 48Moderate | Wayne Pisano director buy | $20k 5,000 shares | +59% | +21% from low-47% from high | |
| 48Moderate | Catherine A. Sohn director buy | $2,118 500 shares | +50% | +21% from low-47% from high | |
| 56Moderate | Diane Jorkasky director buy | $2,003 527 shares | - | +9% from low-52% from high | |
| 53Moderate | John Gill director buy | $51k 12,500 shares | - | +18% from low-50% from high | |
| 53Moderate | Jerome Benedict Durso President and CEO buy | $52k 12,500 shares | - | +22% from low-48% from high | |
| 31Weak | Catherine A. Sohn director buy | $5,785 1,000 shares | - | - | |
| 45Moderate | Gregory L Weaver Chief Financial Officer buy | $52k 10,000 shares | - | - |
Transactions
The newest 50 of 152 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Christophe Arbet-Engels Chief Medical Officer | MOption exercise Common Stock, par value $0.0001 | +37,500 | $0.00 | $0 | 37,500 | 8 d ago |
| Oct 1, 2026 | Gregory L Weaver Chief Financial Officer | MOption exercise Common Stock, par value $0.0001 | +14,475 | $0.00 | $0 | 54,306 | 8 d ago |
| Oct 1, 2026 | Christophe Arbet-Engels Chief Medical Officer | FTax withholding Common Stock, par value $0.0001 | -12,679 | $2.76 | $35k | 24,821 | 8 d ago |
| Oct 1, 2026 | Gregory L Weaver Chief Financial Officer | FTax withholding Common Stock, par value $0.0001 | -4,379 | $2.76 | $12k | 49,927 | 8 d ago |
| Oct 1, 2026 | Gregory L Weaver Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative | -14,475 | $0.00 | $0 | 43,425 | 8 d ago |
| Oct 1, 2026 | Christophe Arbet-Engels Chief Medical Officer | MOption exercise Restricted Stock Unitsderivative | -37,500 | $0.00 | $0 | 112,500 | 8 d ago |
| Oct 1, 2026 | Richard Thomas Menziuso Principal Accounting Officer | AGrant or award Stock Options (option to buy)derivative | +84,546 | $0.00 | $0 | 84,546 | 11 d ago |
| Oct 1, 2026 | Richard Thomas Menziuso Principal Accounting Officer | AGrant or award Restricted Stock Unitsderivative | +36,234 | $0.00 | $0 | 36,234 | 11 d ago |
| Sep 16, 2026 | Linda M Richardson Chief Commercial Officer | MOption exercise Common Stock, par value $0.0001 | +24,000 | $0.00 | $0 | 24,000 | 26 d ago |
| Sep 16, 2026 | Linda M Richardson Chief Commercial Officer | FTax withholding Common Stock, par value $0.0001 | -6,826 | $3.24 | $22k | 17,174 | 26 d ago |
| Sep 16, 2026 | Linda M Richardson Chief Commercial Officer | MOption exercise Restricted Stock Unitsderivative | -24,000 | $0.00 | $0 | 72,000 | 26 d ago |
| May 1, 2026 | Philip Hodges director | AGrant or award Stock Options (option to buy)derivative | +48,800 | $0.00 | $0 | 48,800 | May 1, 2026 |
| May 1, 2026 | Teri L Lawver director | AGrant or award Stock Options (option to buy)derivative | +48,800 | $0.00 | $0 | 48,800 | May 1, 2026 |
| May 1, 2026 | Klaus Schafer director | AGrant or award Stock Options (option to buy)derivative | +48,800 | $0.00 | $0 | 48,800 | May 1, 2026 |
| May 1, 2026 | Wayne Pisano director | AGrant or award Stock Options (option to buy)derivative | +48,800 | $0.00 | $0 | 48,800 | May 1, 2026 |
| May 1, 2026 | Mitchel Sayare director | AGrant or award Stock Options (option to buy)derivative | +48,800 | $0.00 | $0 | 48,800 | May 1, 2026 |
| May 1, 2026 | John Gill director | AGrant or award Stock Options (option to buy)derivative | +48,800 | $0.00 | $0 | 48,800 | May 1, 2026 |
| May 1, 2026 | Diane Jorkasky director | AGrant or award Stock Options (option to buy)derivative | +48,800 | $0.00 | $0 | 48,800 | May 1, 2026 |
| May 1, 2026 | Catherine A. Sohn director | AGrant or award Stock Options (option to buy)derivative | +48,800 | $0.00 | $0 | 48,800 | May 1, 2026 |
| Apr 6, 2026 | John Gill director | POpen-market purchase Common Stock, par value $0.0001 | +9,200 | $3.41 | $31k | 21,700 | Apr 6, 2026 |
| Apr 1, 2026 | Gregory L Weaver Chief Financial Officer | POpen-market purchase Common Stock, par value $0.0001 | +10,000 | $3.15 | $31k | 38,078 | Apr 1, 2026 |
| Apr 1, 2026 | Jerome Benedict Durso President and CEO | POpen-market purchase Common Stock, par value $0.0001 | +15,000 | $3.14 | $47k | 47,500 | Apr 1, 2026 |
| Mar 6, 2026 | Gregory L Weaver Chief Financial Officer | POpen-market purchase Common Stock, par value $0.0001 | +5,000 | $3.54 | $18k | 28,078 | Mar 9, 2026 |
| Mar 6, 2026 | Jerome Benedict Durso President and CEO | POpen-market purchase Common Stock, par value $0.0001 | +20,000 | $3.54 | $71k | 32,500 | Mar 9, 2026 |
| Feb 26, 2026 | Gregory L Weaver Chief Financial Officer | AGrant or award Stock Options (option to buy)derivative | +259,000 | $0.00 | $0 | 259,000 | Feb 27, 2026 |
| Feb 26, 2026 | M Scot Roberts Chief Scientific Officer | AGrant or award Stock Options (option to buy)derivative | +222,670 | $0.00 | $0 | 222,670 | Feb 27, 2026 |
| Feb 26, 2026 | Gregory L Weaver Chief Financial Officer | AGrant or award Restricted Stock Unitsderivative | +111,000 | $0.00 | $0 | 111,000 | Feb 27, 2026 |
| Feb 26, 2026 | M Scot Roberts Chief Scientific Officer | AGrant or award Restricted Stock Unitsderivative | +95,430 | $0.00 | $0 | 95,430 | Feb 27, 2026 |
| Jan 30, 2026 | M Scot Roberts Chief Scientific Officer | MOption exercise Common Stock, par value $0.0001 | +9,275 | $0.00 | $0 | 104,670 | Feb 3, 2026 |
| Jan 30, 2026 | M Scot Roberts Chief Scientific Officer | FTax withholding Common Stock, par value $0.0001 | -2,859 | $5.60 | $16k | 101,811 | Feb 3, 2026 |
| Jan 31, 2026 | M Scot Roberts Chief Scientific Officer | AGrant or award Common Stock, par value $0.0001 | +5,567 | $3.07 | $17k | 107,378 | Feb 3, 2026 |
| Feb 2, 2026 | M Scot Roberts Chief Scientific Officer | MOption exercise Common Stock, par value $0.0001 | +7,775 | $0.00 | $0 | 115,153 | Feb 3, 2026 |
| Feb 2, 2026 | M Scot Roberts Chief Scientific Officer | FTax withholding Common Stock, par value $0.0001 | -2,329 | $5.55 | $13k | 112,824 | Feb 3, 2026 |
| Jan 30, 2026 | M Scot Roberts Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative | -9,275 | $0.00 | $0 | 9,275 | Feb 3, 2026 |
| Feb 2, 2026 | M Scot Roberts Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative | -7,775 | $0.00 | $0 | 0 | Feb 3, 2026 |
| Jan 31, 2026 | Raymond M Jordt Chief Business Officer | AGrant or award Common Stock, par value $0.0001 | +4,571 | $3.07 | $14k | 70,107 | Feb 2, 2026 |
| Jan 30, 2026 | Vipin K Garg President and CEO | MOption exercise Common Stock, par value $0.0001 | +26,775 | $0.00 | $0 | 429,225 | Feb 2, 2026 |
| Jan 30, 2026 | Vipin K Garg President and CEO | FTax withholding Common Stock, par value $0.0001 | -11,632 | $5.60 | $65k | 417,593 | Feb 2, 2026 |
| Jan 31, 2026 | Vipin K Garg President and CEO | AGrant or award Common Stock, par value $0.0001 | +6,926 | $3.07 | $21k | 424,519 | Feb 2, 2026 |
| Jan 30, 2026 | Vipin K Garg President and CEO | MOption exercise Restricted Stock Unitsderivative | -26,775 | $0.00 | $0 | 26,775 | Feb 2, 2026 |
| Jan 27, 2026 | Vipin K Garg President and CEO | MOption exercise Common Stock, par value $0.0001 | +41,200 | $0.00 | $0 | 420,348 | Jan 29, 2026 |
| Jan 27, 2026 | M Scot Roberts Chief Scientific Officer | MOption exercise Common Stock, par value $0.0001 | +15,850 | $0.00 | $0 | 100,143 | Jan 29, 2026 |
| Jan 27, 2026 | Raymond M Jordt Chief Business Officer | MOption exercise Common Stock, par value $0.0001 | +15,850 | $0.00 | $0 | 69,765 | Jan 29, 2026 |
| Jan 27, 2026 | Vipin K Garg President and CEO | FTax withholding Common Stock, par value $0.0001 | -17,898 | $6.18 | $111k | 402,450 | Jan 29, 2026 |
| Jan 27, 2026 | M Scot Roberts Chief Scientific Officer | FTax withholding Common Stock, par value $0.0001 | -4,748 | $6.18 | $29k | 95,395 | Jan 29, 2026 |
| Jan 27, 2026 | Raymond M Jordt Chief Business Officer | FTax withholding Common Stock, par value $0.0001 | -4,229 | $6.18 | $26k | 65,536 | Jan 29, 2026 |
| Jan 27, 2026 | Vipin K Garg President and CEO | MOption exercise Restricted Stock Unitsderivative | -41,200 | $0.00 | $0 | 123,600 | Jan 29, 2026 |
| Jan 27, 2026 | M Scot Roberts Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative | -15,850 | $0.00 | $0 | 47,550 | Jan 29, 2026 |
| Jan 27, 2026 | Raymond M Jordt Chief Business Officer | MOption exercise Restricted Stock Unitsderivative | -15,850 | $0.00 | $0 | 47,550 | Jan 29, 2026 |
| Jan 25, 2026 | Vipin K Garg President and CEO | MOption exercise Common Stock, par value $0.0001 | +42,050 | $0.00 | $0 | 397,132 | Jan 27, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Christophe Arbet-EngelsChief Medical Officer
- Jerome Benedict DursoPresident and CEO
- John Gilldirector
- Vipin K GargPresident and CEO
- Philip Hodgesdirector
- Raymond M JordtChief Business Officer
- Diane Jorkaskydirector
- Teri L Lawverdirector, officer
- Richard Thomas MenziusoPrincipal Accounting Officer
- Wayne Pisanodirector
- Linda M RichardsonChief Commercial Officer
- M Scot RobertsChief Scientific Officer
- Mitchel Sayaredirector
- Klaus Schaferdirector
- Catherine A. Sohndirector
- Gregory L WeaverChief Financial Officer
Questions about ALT
Answered from the filings on this page, as of the latest one.
Are insiders buying ALT?
No. In the last 90 days no insider at Altimmune, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade ALT on the open market?
John Gill (director) bought $31k of ALT on Apr 6, 2026 and filed the Form 4 on Apr 6, 2026. InsiderTell scored 53 (moderate), with 3 insiders on the same side within 14 days.
How many insiders file Form 4 at Altimmune, Inc.?
16 people have filed a Form 4 at Altimmune, Inc., among them Christophe Arbet-Engels (Chief Medical Officer), Jerome Benedict Durso (President and CEO), John Gill (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.